We could not find any results for:
Make sure your spelling is correct or try broadening your search.
ESSA Pharma Inc is a pharmaceutical company. The company is in the preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen recepto... ESSA Pharma Inc is a pharmaceutical company. The company is in the preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Show more
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer PR Newswire SOUTH SAN...
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress Canada NewsWire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 13, 2024 Combination of...
ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference Canada NewsWire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 11, 2024 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.03 | -1.68539325843 | 1.78 | 1.85 | 1.73 | 246474 | 1.77545923 | CS |
4 | 0.13 | 8.02469135802 | 1.62 | 1.89 | 1.6 | 541173 | 1.75634258 | CS |
12 | -4.02 | -69.6707105719 | 5.77 | 7.69 | 1.4 | 880075 | 1.67781642 | CS |
26 | -5.07 | -74.3401759531 | 6.82 | 7.69 | 1.4 | 437264 | 1.91695389 | CS |
52 | -3.69 | -67.8308823529 | 5.44 | 11.67 | 1.4 | 275050 | 3.18549225 | CS |
156 | -11.17 | -86.4551083591 | 12.92 | 14.88 | 1.4 | 487107 | 4.26301022 | CS |
260 | -4 | -69.5652173913 | 5.75 | 36 | 1.4 | 376554 | 6.98878069 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions